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Abstract: Diabetes mellitus (DM), the most common of metabolic disorders, is a global 
public health concern. Numbers are rising with 383 million adults currently diagnosed with 
DM and another 175 million as yet undiagnosed. The rise in cases includes increasing numbers 
of women of a reproductive age whose reproductive health and contraception need careful 
consideration. Unintended pregnancy with poor glycemic control at the time of conception 
increases the chance of adverse pregnancy outcomes including stillbirth, congenital abnormali-
ties, and perinatal mortality. In order to minimize complications, safe and effective contracep-
tion is paramount for all women with DM. This is a challenge as women have been found to be 
reticent to ask for advice, appear to lack understanding of risks, and are less likely to be using 
contraception than women without DM. The World Health Organization has developed Medical 
Eligibility Criteria to guide contraceptive choice. Women with DM without complications can 
choose from the full range of contraceptive methods including hormonal contraception as the 
advantages of use outweigh any risk. Women with diabetic complications may need specialist 
advice to assess the risk–benefit equation, particularly in respect of hormonal contraception. 
Women should be aware that there is no restriction to the use of oral and copper intrauterine 
emergency contraception methods. There is a need for an integrated approach to diabetes and 
reproductive health with improved communication between women with DM and their health 
care providers. Women need to be aware of advice and services and should make their own 
choice of contraception based on their needs and associated risk factors. Practitioners can offer 
nonjudgmental guidance working in partnership with women. This will enable discussion of 
risks and benefits of contraceptive methods and provision of advice dedicated to improving 
overall health and well-being.
Keywords: diabetes mellitus, gestational diabetes, contraception, education, preconception 
counseling
Introduction
Diabetes mellitus (DM), the most common of metabolic disorders,1 is a global public 
health concern. Three hundred and eighty three million adults are currently diagnosed 
with DM and another 175 million are estimated to be living with the condition but are 
as yet undiagnosed.2 By 2035, numbers are set to increase by 55% with 592 million 
people becoming affected worldwide.2 The rise in cases includes increasing numbers 
of women of reproductive age whose reproductive health and contraceptive needs must 
be carefully considered as DM has serious implications for pregnancy. It is the most 
common medical condition complicating pregnancy and affects up to 10% of women 
of a reproductive age in developed countries.3
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There are three main types of DM (Table 1). Type 1 DM 
is an autoimmune, chronic condition occurring in both adults 
and children, often before 40 years of age, and accounting 
for ∼10% of cases in adults and 98% of cases in children.4 
In type 1 DM, the primary beta cells of the pancreas do not 
produce insulin resulting in hyperglycemia. The propensity 
to develop autoimmune diseases, such as diabetes, may be 
familial. Treatment involves careful glucose monitoring and 
administration of insulin.
Type 2 DM, accounting for ∼90% of cases in adults and 
2% of cases in children,4 is sometimes known as mature 
onset diabetes. This occurs when the amount of insulin 
produced by the pancreatic beta cells is insufficient or if the 
body develops a resistance to the insulin produced. As this 
condition is often associated with obesity, treatment involves 
diet and exercise, oral medication, and occasionally insulin. 
Recently, more cases of type 2 DM have been diagnosed in 
younger age groups due to increasing obesity.1
Gestational DM (GDM) develops during pregnancy in 
women without previously diagnosed DM. It is caused by 
increased blood glucose levels in pregnancy and is treated 
with diet or insulin. GDM usually disappears after preg-
nancy but women are at risk of developing type 2 DM in 
the future.
This paper will review some of the challenges for women 
with DM in relation to contraception and will suggest solu-
tions guided by current evidence.
Methods
To update previous searches for new primary research and 
reviews, we searched MEDLINE (754 articles), PsycINFO 
(95 articles), CAB Abstracts (451 articles), CINAHL 
(174 articles), Maternity and Infant Care (49 articles), Web 
of Science (53 articles), British Nursing Index (35 articles), 
Embase (150 articles), and ScienceDirect (76 articles) from 
2008 to 2015. The following terms were used for MEDLINE 
and Maternity and Infant Care; these terms were amended 
for the other databases.
“Contraception”, “birth control”, “intrauterine device/
IUD”, “Levonorgestrel intrauterine system/IUS”, “vagi-
nal ring”, “barrier method”, “hormonal contraception”, 
“contraceptive implant”, “family planning”, “reproductive 
health”, “contraceptive counseling”, “hormonal contracep-
tion”, “sterilization”, “contraceptive injection”, “diabetes”, 
“diabetes mellitus”, “type 1 diabetes”, “type 2 diabetes”, 
“women with diabetes”.
The terms were searched separately and in combination. 
References given in the listed papers were searched for papers 
that did not appear on any of the databases searched. The 
search was limited to studies in the English language. Articles 
that addressed the issues of contraception use in women with 
diabetes were qualified for inclusion in the review. The search 
yielded 1,837 results; most of these were duplicates due to the 
combination of search terms within the different databases. 
The titles and abstracts of 1,837 studies were screened, 
and those articles whose eligibility could not be determined 
from their titles and abstracts alone were read in full. The full 
text of 28 studies was read and 17 studies were found to be 
relevant. The relevant studies included reviews and primary 
quantitative and qualitative research studies.
Facing the challenges
DM can lead to numerous complications with long-term 
health implications on vascular, neurological, renal, and 
ophthalmic functions.5 From a reproductive perspective, poor 
glycemic control at the time of conception and during preg-
nancy increases the chance of adverse pregnancy outcomes 
including stillbirth, congenital abnormalities, and perinatal 
mortality.6 Neonates born to women with DM are “five times 
as likely to be stillborn, three times as likely to die in their first 
months of life, and twice as likely to have a major congenital 
anomaly”.7 The UK Mothers and Babies: Reducing Risk 
through Audits and Confidential Enquiries across the UK 
(MBRRACE) report8 highlights other risks associated with 
diabetes and pregnancy, namely, hypoglycemia and diabetic 
ketoacidosis, and the importance of preconception advice 
and glycemic control with an HbA
1c
 ,10%.
In order to minimize complications, safe and effec-
tive contraception to prevent unintended pregnancy and 
preconception care is paramount for all women with DM.9 
Monitoring and improving maternal health whilst encourag-
ing adequate inter-pregnancy spacing and the use of effective 
contraception forms an integral part of pre-pregnancy care.1 
This is a challenge for health care professionals as only half 
Table 1 Prevalence of diabetes
Prevalence of diabetes (2014)2,4
Adults aged 20–79 
years worldwide
387 million people were affected in 2014. This 
figure was calculated to rise to 592 million by 20352
Undiagnosed  
type 2 diabetes
179 million people were calculated to have 
undiagnosed type 2 Diabetes4
Type 1 and type 2 
diabetes
Type 1 diabetes – 10% of those affected 
Type 2 diabetes – 90% of those affected4
Global estimations The international Diabetes Federation (iDF) 
documents the countries with the highest number 
of diabetic patients: People’s Republic of China, 
india, USA, Russia, Brazil2
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of the women with DM plan their pregnancies,7 and they can 
be reticent to ask for advice;10 a US National survey found 
that women with DM were less likely to be using contracep-
tion than women without DM.11
Lack of understanding about the high risks for unplanned 
pregnancy and diabetes and the need for effective contracep-
tion among women with DM are of concern. Cartwright et al12 
published findings of an audit involving 100 women attending 
a diabetic clinic in UK. Findings revealed that two-thirds of 
women were not able to remember discussing pregnancy or 
contraception with a health care provider. The most common 
method of contraception (65%) was the use of condoms and 
some women were unsure about suitable contraception. Those 
having had a pregnancy exhibited no additional knowledge 
regarding risks associated with pregnancy and DM.
Murphy et al13 explored the experiences of women with 
DM who did not attend pre-pregnancy care in the UK. Twenty-
nine pregnant women with type 1 and type 2 DM participated 
in a qualitative study. Data were collected via semi-structured 
interviews and coded as part of thematic analysis. Women 
were found to have difficulty complying with contraceptive 
advice and the majority were not using reliable contraception 
prior to becoming pregnant. With regard to preconception 
health, although some women had experienced previous 
miscarriage, fetal anomaly, and stillbirth, they had however 
been reluctant to attend preconception care due to previous 
negative experiences, becoming pregnant quickly, having 
concerns relating to fertility, or simply due to practicalities 
associated with attending services.
The prevalence of DM is rising rapidly in the Middle 
Eastern countries and the developing world,2 and two stud-
ies from Iran have identified low use of contraception by 
women with DM.14,15 A mixed method cross-sectional study 
involving 200 women identified many pregnancy-related 
abnormalities and a lack of confidence in using contracep-
tives, with many women not using any form of contraception. 
Similar findings and low use of modern contraceptive meth-
ods with women mainly using coital withdrawal method were 
found in Iranian women with type 2 DM, hypertension, or 
obesity.15 Although the results of these studies may not be 
generalizable to different demographic communities, the 
importance of educating women with DM from all groups 
of society needs to be emphasized.
The challenge is to support women with type 1 and type 2 
DM in making a choice of contraception based on their indi-
vidual needs and associated risk factors.16 No restrictions for 
use of any contraceptive apply to women with GDM, but their 
propensity to develop type 2 DM may need consideration. 
Young people with unstable DM are of particular concern as 
they need reliable contraception in order to prevent high-risk 
unintended pregnancies.
Providing contraceptive solutions
Guidance about contraception needs to be offered holistically 
and a trusting relationship between practitioner and client is 
advocated.17 The importance of avoiding unintended pregnancy 
should be an integral part of diabetes education from adoles-
cence onward discussed by diabetes health care providers.9 
Choice of contraception should be made on the preference of 
the woman and individual risk factors identified such as the 
presence of vascular, nephropathy, neuropathy, or retinal dis-
ease.1,18 Choosing a safe and reliable method of contraception 
for a woman with DM needs careful consideration and practi-
tioners need to make reference to the WHO Medical Eligibility 
Criteria for Contraceptive Use18 as outlined in Table 2.
Efficacy must be assured and the chosen method must not 
induce diabetic-related risks such as thromboembolic and cardio-
vascular complications.19 Those with poorly controlled diabetes 
and obese women may need to be targeted as they often fall 
victim to associated risks by not seeking advice and support.1
Combined hormonal contraception
Combined hormonal contraception (CHC) methods include 
the administration of estrogen and progestogen. Examples 
of CHC include combined contraceptive pills, transdermal 
contraceptive patches, combined vaginal rings, and com-
bined injectable contraception. Historically, women with 
diabetes were denied CHC due to concerns about the effect 
on carbohydrate and lipid metabolism.20 Recent data high-
light the safety of CHC not only in relation to women with 
DM without complications, but in not inducing diabetes in 
otherwise healthy individuals.1,20,21
A recent review of evidence1 emphasized that CHC con-
taining less than 35 µg of ethinyl-estradiol did not alter blood 
glucose concentrations and insulin secretion. In relation to 
Table 2 wHO Medical eligibility Criteria for Contraceptive Use 
(2015)
Category  With clinical judgment
1 Use method in any circumstance
2 Generally use method
3 Use of method not usually recommended unless other 
more appropriate methods are not available or not 
acceptable
4 Method not to be used
Note: Reprinted from wHO. WHO Medical Eligibility Criteria for Contraceptive Use; 
Geneva: 2015. Available from: http://www.who.int/reproductivehealth/publications/
family_planning/mec-wheel-5th/en/. Accessed August 19, 2015.18 Copyright © 2015.
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diabetic retinopathy, macular edema, and nephropathy, there 
was no increase in risk or acceleration of disease in women 
taking oral CHC.1,19 The WHO Medical Eligibility Criteria for 
Contraceptive Use18 states (Table 3) that for any diabetic patient 
without cardiovascular or microvascular complications, advan-
tages of using the method generally outweigh the theoretical 
or proven risks, and Category 2 applies for CHC.
The results of a Cochrane review of randomized con-
trolled trials by Visser et al21 was inconclusive in determining 
whether hormonal contraception affected carbohydrate and 
lipid metabolism and long-term complications in women with 
DM. The French Society of Endocrinology expert group,22 
however, undertook a comprehensive review of evidence and 
pathophysiological data, as to the safe contraceptive options 
for diabetic women with risk factors, and concluded that from 
a hormonal perspective extreme caution is recommended as 
risk factors often do not occur in isolation. Gourdy1 in his 
review supports this and suggests that CHC with estrogens 
and progestogen should be avoided whatever their route of 
administration in women with DM who have microvascular 
complications such as severe retinopathy (ischemic or prolif-
erative), active macular edema, or nephropathy with persistent 
proteinuria. In cases of DM complicated by cardiovascular or 
microvascular disease, the risks of prescribing CHC outweigh 
any advantages and a WHO Medical Eligibility Criteria 
(MEC) 3/418 would be awarded.1,22,23 CHC is also unlikely 
to be suitable for women with risk factors such as smoking, 
obesity, or hypertension due to increased risk of venous throm-
boembolism, myocardial infarction, and stroke.17,23
Progestogen oral hormonal 
contraception
The progestogen-only pill (POP) is regarded as a safe option 
for women with DM of any age with or without complications. 
Advantages of using the method generally outweigh the theo-
retical or proven risks (WHO MEC 218). The POP needs to be 
taken within a daily set time period but compliance is likely 
to be good if scheduled with routine insulin or oral hypogly-
cemic medication. Desogestrel has the benefit of inhibiting 
ovulation in 97% of cases and a 12 hours dosing period,24 
and therefore may be a more reliable choice especially for 
younger people with DM.
Long-acting reversible 
contraception
Long-acting reversible contraceptives (LARC) are not 
memory-dependent and have high efficacy, which can 
make them a good choice for women with DM. Methods 
include copper intrauterine device (IUD), intrauterine 
system (IUS), progestogen-only injectable contraceptives, 
progestogen-only subdermal implants, and combined vaginal 
ring. The combined vaginal ring has been included under 
CHC within this review. Despite their safety and effective-
ness, LARCs are generally underutilized with only 15.5% 
of women worldwide using IUDs, and only 3.4% using 
subdermal implants.25 In the UK in 2008–2009, only 12% 
of women aged 16–49 years used LARC compared to 25% 
of women who used COC and 25% whose male partners 
used condoms.26
Goldstuck and Steyn27 published a systematic review 
focusing on the efficacy of the IUD and IUS for women with 
DM. Four hundred and ninety nine articles were screened and 
seven studies met the inclusion criteria. Analysis resulted in 
the reassurance that the copper IUD and IUS were suitable 
for women with type 1 and type 2 DM, although the IUS 
needed further monitoring from a metabolic perspective in 
relation to type 2 DM. WHO MEC18 agrees that the IUD is 
entirely suitable for women with type 1 or type 2 DM with no 
restriction for use, and the advantages of using IUS generally 
outweigh the theoretical or proven risks.
A Cochrane review by Visser et al21 focused on evidences 
from randomized controlled trials relating to hormonal as 
opposed to nonhormonal contraception in diabetic patients. 
Results concluded that there was limited evidence relating to 
the effect of hormonal contraception on diabetes. Although 
the quality of the data was inconclusive, it identified the POP 
and the IUS as not being contraindicated for women with 
DM, whereas the CHC was identified as having a negligible 
effect on glucose stability.
Progestogen-only injectable contraceptives, such as 
medroxyprogesterone acetate and norethindrone enanthate, 
are suitable for women with DM without complications.26 
Concerns regarding possible negative effect on lipid 
Table 3 Contraceptive methods and diabetes
Condition CHC POP DMPA/
NET-EN
IMP Cu 
IUD
IUS
History of gestational 
diabetes
1 1 1 1 1 1
Nonvascular disease 
 i. Noninsulin dependent 
ii. insulin dependent
 
2 
2
 
2 
2
 
2 
2
 
2 
2
 
1 
1
 
2 
2
Neuropathy/retinopathy/
neuropathy
3/4 2 3 2 1 2
Other vascular disease 3/4 2 3 2 1 2
Abbreviations: CHC, combined hormonal contraception; Cu iUD, copper 
intrauterine device; DMPA/NeT-eN, medroxyprogesterone acetate/Norethisterone 
enanthate; iMP, implants; POP, progestogen-only pill; iUS, intrauterine system.
Note: Reprinted from wHO. WHO Medical Eligibility Criteria for Contraceptive Use; 
Geneva: 2015. Available from: http://www.who.int/reproductivehealth/publications/
family_planning/mec-wheel-5th/en/. Accessed August 19, 2015.18 Copyright © 2015.
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metabolism due to hypoestrogenic effects and reduced 
HDL levels mean that for women with complications, risk 
outweighs benefit (MEC 3/4), and POPs would only be 
administered following specialist advice.18 Injectable meth-
ods may also cause a possible delay returning to fertility,26 
which may be unacceptable to women with DM who may 
prefer to have families as soon as possible before complica-
tions of DM arise.
Progestogen-only subdermal implants containing 
etonogestrel are suitable for women with diabetes, as per 
WHO MEC guidelines.18 Implants release a constant dose 
of progestogen reducing the potential for metabolic variation 
and maintaining steady blood-lipid ratios.28
Barrier and natural methods of 
contraception
Barrier methods include a range of contraceptives includ-
ing diaphragms, cervical caps, as well as male and 
female condoms. Some involve using spermicide such as 
nonoxynol-9; however, there appear to be no studies contrain-
dicating the use of spermicide from a diabetic perspective. 
The decision to use a barrier method comes down to personal 
acceptability and efficacy; a male condom, for example, is 
98% effective with proper use, a female condom 95%, and 
a diaphragm with spermicide is 92%–96% effective.29 Using 
barrier methods alone may be too unreliable in preventing 
pregnancy for women with DM, especially if she is trying to 
lose weight or reduce her HbA
1c
 levels.26 Male and female 
condoms may be best used to prevent sexually transmitted 
infections, in conjunction with a more effective contraceptive 
such as hormonal methods or IUD.
Fertility awareness methods, although effective for 
some couples striving for a non-hormonal, more “natural” 
method of contraception, may not be a suitable choice 
for women with DM. In healthy women with a regular 
menstrual cycle and contemporaneous use, natural family 
planning is rated as being 99% effective.29 Women with DM 
have a potentially increased incidence of erratic menstrual 
cycles30 that may affect efficacy and lead to an increased 
failure rate.31
Male and female sterilization
The failure rate for female sterilization is one in 200 and 
one in 2,000 for men following a vasectomy.29 Since both 
procedures involve an operative intervention, however, minor, 
glycemic control needs consideration since it can affect the 
chances of acquiring a postoperative infection.32 In addition, 
the chances of hypoglycaemia and ketoacidosis occurring, 
increase post surgery complications.33 Guidance from a 
diabetic physician regarding the safest operative location 
as well as prophylactic antibiotics are advisable if a couple 
decides that sterilization is the right choice.18
Emergency contraception
Emergency contraception provides all women with addi-
tional choice for prevention of pregnancy. The global rate of 
unplanned pregnancy in 2012 was 53 per 1,000 women aged 
between 15 years and 44 years.34 Emergency contraception 
may be required for multiple reasons including failure to 
use a contraceptive correctly and following sexual abuse 
or rape. Women with DM at risk and not wanting to be 
pregnant are advised to seek emergency contraception at 
the earliest opportunity. From a diabetic perspective, there 
are no contraindications to taking emergency progestogen-
only contraceptive pills within the recommended time frame 
or to the use of the copper-bearing IUD within 5 days of 
unprotected intercourse or when ovulation is known, no 
more than 5 days after ovulation.35 According to the WHO 
MEC guidelines,18 the benefit of using emergency con-
traception outweighs the risk, even where there is severe 
vascular disease.
Key solutions
Our review has highlighted that women with DM need to use 
a reliable method of contraception in order to avoid high-risk 
unintended pregnancies. Women without complications can 
choose from the full range of methods that are available;18 
however, studies have shown that they are less likely to use 
contraception or to seek advice.10,11 To improve pregnancy 
outcomes, women with DM need to be made aware of fertil-
ity and contraception advice services available within both 
acute and primary care.
Taking the earlier discussions into account, it is of con-
cern that not all women with DM appear to understand the 
importance of contraceptive and/or preconception well-being 
from a diabetic perspective. Contraception messages in the 
diabetic female population need to be reinforced.12–15
There is a need for a more integrated approach to diabe-
tes and reproductive health with improved communication 
between women with DM and their health care providers.13 
Diabetes health professionals need to discuss contraception 
with women and referral to a contraceptive specialist for 
advice may be advisable.22,36
UK guidelines16 emphasize that women should choose 
their own contraceptive method, based on guidelines and 
taking account of any risks. In order to make appropriate 
choices, women with DM need to be provided with up-to-
date research-based evidence regarding suitable methods. 
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The effectiveness of barrier methods and oral contraception 
is often compromised due to inconsistent use,26 and LARC 
methods, if suitable, will provide better efficacy.26
Women with DM need to plan any pregnancies and use 
reliable contraception until their diabetic health care provider 
confirms a satisfactory HbA
1c
 result, ideally below 6.5%.9 
Women should be advised to maintain their “fasting blood 
glucose between 3.5 and 5.9 mmol/L and their 1-hour post-
prandial blood glucose below 7.8 mmol/L if this is safely 
achievable”.37 They do, however, need to be aware of the 
potential risk of hypoglycemic episodes and the appropri-
ate treatment required. Women with an HbA
1c
 level above 
86 mmol/mol (10%) are advised not to become pregnant 
due to associated risks.9 Before discontinuing contraception, 
a comprehensive drug assessment should be made to review 
and change medication that is potentially teratogenic, such as 
ACE inhibitors and certain insulins.9,38 In addition, women 
should be offered a renal assessment including measure-
ment of microalbuminuria and retinal assessment to exclude 
progressive disease.9,38
Support and education prior to pregnancy, therefore, 
benefits by ensuring an optimal pre-pregnancy weight, 
stabilizing glycemic control, ensuring safety of medication, 
and providing baseline levels for monitoring retinal and 
renal functions.9,38 Delay of pregnancy to achieve favorable 
glycemic control has been found to prevent poor maternal 
and neonatal outcomes,6 and in most cases, maintaining 
an optimal inter-pregnancy interval reduces adverse birth 
outcomes and decreases maternal morbidity from a physical 
and psychological perspective.39,40
Monitoring and improving health while encouraging 
adequate use of effective contraception forms an integral part 
of contraceptive care. Follow-up for women with DM using 
hormonal contraception is based on routine clinical practice 
of blood pressure and body mass index measurements, but 
baseline lipid profiles may need assessment, especially if 
injectable contraception is used, and blood glucose levels 
as relevant.19
In conclusion, the prevalence of DM in women of repro-
ductive age is rising. Effective contraception is required 
in order to prevent unintended pregnancy as uncontrolled 
glucose levels at conception leads to poor maternal and 
perinatal outcomes. Contraceptive choices need to be made 
by women in conjunction with evidence-based research 
(Table 4). Women with DM without complications have 
multiple choices for contraception and those with complica-
tions may need specialist advice. Communication between 
health professionals and women with DM needs improving in 
relation to promoting reproductive health and contraception. 
A trusting, nonjudgmental approach and a positive relation-
ship are important. This will enable the discussion of risks 
and benefits of contraceptive methods and provision of advice 
dedicated to improving overall health and well-being.
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